Abstract
A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.
Author supplied keywords
Cite
CITATION STYLE
Li, W., Sanchez-Hidalgo, A., Jones, V., De Moura, V. C. N., North, E. J., & Jackson, M. (2017). Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. Antimicrobial Agents and Chemotherapy, 61(4). https://doi.org/10.1128/AAC.02399-16
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
